Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Fong, Zhi Ven, and Carlos Fernández-del Castillo. 2015. “Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy.” Viszeralmedizin 31 (1): 43-46. doi:10.1159/000373912. http://dx.doi.org/10.1159/000373912.

Published Version
doi:10.1159/000373912

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658393

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy

Zhi Ven Fong  Carlos Fernández-del Castillo

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Keywords
Intraductal papillary mucinous adenocarcinoma · Prognostic factors · Adjuvant therapy

Introduction

Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are mucin-producing cystic lesions involving the main pancreatic duct or its side branches that lack the ovarian stroma characteristically seen in mucinous cystic neoplasms. Likely a result of advances in cross-sectional imaging, these cystic lesions are being diagnosed and treated at an exponential rate over the past decade [1, 2]. Our understanding of the biology of IPMNs has evolved as pancreatic surgeons and gastroenterologists manage and follow these patients with increasing frequency. To date, IPMNs are regarded as a disease spectrum ranging from benign adenoma to in situ carcinoma and invasive carcinoma, and also possibly as a ‘field defect’.

Most IPMNs are often diagnosed incidentally as benign cystic lesions with excellent survival outcomes, with most patients never succumbing to the disease [3]. The risk of malignant transformation hinges on the degree of main-duct involvement: main-duct IPMNs (MD-IPMN) harbor a malignancy risk of as high as 70%, whereas branch-duct IPMNs (BD-IPMN) have a malignancy risk which is about 25% in tumors that are resected [4–10], but in reality is much lower since the vast majority are managed non-operatively. Although the outcomes following resection of pancreatic ductal adenocarcinoma (PDAC) have been historically poor (5-year survival rates of 10–20%) [11, 12], the outcomes for IPMNs with associated invasive carcinoma, termed intraductal papillary mucinous adenocarcinoma (IPMC) for the purpose of this review, have been more favorable, with reported 5-year survival rates of about 40% [13–16]. It was not until recently that IPMCs were analyzed based on their histopathological subtypes (colloid, tubular) and epithelial phenotypes (gastric, intestinal, pancreatobiliary, oncocytic). Within this article, we will review the clinical outcomes and prognostic factors of IPMC, specifically comparing it to the conventional PDAC, recurrence patterns, and the role of adjuvant therapy. It is important to note that PDACs arising from IPMNs are distinct entities from PDACs occurring concomitant to IPMNs.
Clinical Outcomes and Prognostic Factors

IPMCs are categorized by two distinctive histopathological subtypes with prognostic implications, i.e. colloid and tubular carcinoma. The tubular variant of IPMCs is characterized by neoplastic cells arranged in tubular glands with desmoplastic invasion, similar to that as seen in PDACs. They are generally associated with IPMNs of the pancreatobiliary subtype, expressing MUC1 glycoproteins that are also expressed in conventional PDACs on immunohistochemical examination. Colloid carcinomas are characterized stromal pools of acellular matrix containing neoplastic epithelial cells. As opposed to tubular IPMCs, colloid IPMCs typically are of the intestinal subtype, expressing MUC2 and CDX2 glycoproteins, markers of intestinal differentiation, and are biologically more indolent [17–19].

Besides the aforementioned molecular difference, these two entities are biologically distinct as well. Tubular and colloid IPMCs have significantly different survival outcomes. Tubular IPMCs are generally regarded to be a prognostically poorer subtype similar to that of PDACs, with 5-year survival rates ranging from 37 to 55% following surgical resection. In contrast, colloid IPMCs are often associated with excellent outcomes, with 5-year survival rates ranging from 61 to 87% post-resection [13, 15, 17–19] (fig. 1). This contrast in survival between both entities is largely attributed to the more aggressive oncobiology observed in tubular IPMCs, which often presented at advanced tumor (T) stages and have a higher likelihood of perineural invasion and lymph node metastases [15–17, 19]. In fact, lymph node involvement appears to be such a significant surrogate of invasive disease biology that patients with tubular IPMCs with negative regional lymph nodes have 5-year survival rates (73%) similar to that of colloid IPMCs, but similar to that of PDACs (27%) when there is regional lymph node involvement [16, 19]. In a collaboration study between our institution and the Verona’s group, lymph node ratio (LNR) was the strongest prognostic factor after resection for IPMCs (hazard ratio 6.15 when LNR > 0.2; p < 0.0001) (fig. 2) [20], supporting the notion that lymph node involvement is an important biological surrogate that could guide patient selection for adjuvant therapy.

It is also important to note that while IPMNs with a gastric epithelial background are more frequently associated with BD-IPMNs and are less frequently invasive, its prognosis, when invasive progression has occurred, is significantly worse when compared to non-gastric IPMNs. In a study of 61 patients with IPMCs, we previously reported that the overall survival for patients with gastrictype IPMCs were significantly worse than the non-gastric IPMCs (median survival 28 months for gastric type vs. 89 months for non-gastric type; p = 0.016) [17]. A recent Japanese study of 56 patients with IPMCs corroborated the findings (5-year survival rates of 52.7% and 89.7% in gastric- and intestinal-type IPMCs, respectively; p = 0.03) [21]. This suggests that the epithelial background plays an equal, if not, more important role than the histopathological subtype in defining the biology and prognosis of IPMCs.

Comparison to Pancreatic Adenocarcinoma

Historically, IPMCs are regarded to have superior survival outcomes when compared to conventional PDACs (5-year survival rates of 36–54% observed in IPMCs vs. 12–21% in PDACs). However, most early reports lack dichotomization of IPMCs to its colloid and tubular variant when comparing survival outcomes. More recent contemporary analyses have revealed that the superior survival outcomes of IPMCs are largely attributed to the indolent nature of colloid carcinomas and the fact that a larger proportion of tubular carcinomas have negative lymph nodes when compared to conventional PDAC. The prognosis of tubular variant IPMCs is
The role of adjuvant chemoradiation in invasive IPMNs is not well defined, with a scarcity of high-quality data in the literature. It is hypothesized that because the carcinogenesis of IPMNs may differ from conventional PDACs (DP4 loss and p16 mutation are less common in IPMNs) [26–28], chemosensitivities may differ too. Many oncologists are hesitant in recommending adjuvant therapy to this cohort of patients because data demonstrating a benefit are lacking. In contrast, proponents extrapolate preexisting data available for the more common PDAC [29, 30]. In a retrospective review of our institution’s cohort (n = 200), patients with invasive IPMNs receiving chemoradiation had a similar overall and cancer-specific survival when compared to those that did not. However, the group that received chemoradiation presented at higher stages (p = 0.035) and had a higher frequency of positive nodes (p = 0.024) [31]. On the one hand, the Johns Hopkins group reported congruent outcomes, demonstrating that adjuvant chemoradiation conferred a decrease of 57% in confounders-adjusted relative risk of mortality, with patients with positive margins and lymph node involvement benefitting the most from it [32]. The Indiana group, on the other hand, reported differing outcomes. In their cohort of 98 patients, adjuvant chemoradiation did not affect overall survival in both node-positive (17 vs. 22 months; p = 0.67) and node-negative invasive IPMNs (63 vs. 48 months; p = 0.98) [33].

The retrospective and underpowered nature of these data does not allow definitive conclusions to be drawn about adjuvant therapy in patients with invasive IPMNs. Given the biological heterogeneity of IPMNs and the need for accurate histopathological stratification before randomization (based on its prognostic implications), randomized controlled trials, although desirable, will be difficult to implement due to the rarity of the disease. At present, there are no formal evidence-based recommendations against or supporting adjuvant chemoradiation in invasive IPMNs. Our practice has been to offer such treatment in the right context, including all patients with positive nodes and node-negative patients with tubular carcinomas that have more than minimally invasive disease or have other bad features such as perineural invasion, but avoiding it in node-negative colloid carcinomas.

### Conclusion

IPMNs, more commonly occurring in MD-IPMNs, have a better prognosis on the whole when compared to conventional PDAC. This is largely attributed to the superior survival outcomes seen in colloid carcinomas, with 5-year survival rates approaching 61–87%. Conversely, tubular carcinomas often demonstrate more unfavorable clinicopathological features, with a prognosis similar to that of PDACs. Patients with small, tubular carcinomas with no lymph node metastases are more likely to achieve long-term survival. Currently, there is no strong evidence to support adjuvant chemoradiation, and level I data may not be practical because of

### Table 1. Published series reporting 5-year survival outcomes for colloid and tubular IPMNs and PDACs

| First author, year [reference] | n   | 5-year survival, % |
|------------------------------|-----|-------------------|
|                              |     |  | colloid | tubular | PDAC |
| Maire, 2002 [34]             | 73  | 36 | 21a     |
| Sohn, 2004 [13]              | 52  | 43 |         |
| Partelli, 2010 [20]          | 104 | 54.5 |       |
| Yamaguchi, 2011 [15]         | 122 | 37 | 12a     |
| Sadakari, 2010 [35]          | 30  | 67 | 0 20a   |
| Yopp, 2011 [16]              | 59  | 87 | 55 23a  |
| Mino-Kenudson, 2011 [17]     | 61  | 61 | 37 18a  |
| Yamada, 2014 [21]            | 56  | 71 | 57      |

*a = Sample significance at p < 0.05.

n = Sample size of IPMNs.

significantly worse than that of colloid IPMNs, more closely resembling survival outcomes of PDACs (table 1). In a stage-matched control study comparing 61 patients with IPMNs with 570 patients with PDAC, we reported that this survival difference was attributed to more favorable clinicopathological features observed in IPMNs (especially colloid), specifically advanced T stage, nodal metastases, high-grade histology as well as lymphatic, vascular, and perineural invasion [17]. Similarly, in a separate study matching 59 patients with IPMNs with 59 patients with PDAC based on a prevalidated post-resection PDAC nomogram, the Memorial Sloan-Kettering Cancer Center group reported estimated 5-year survival rates of 87, 55, and 23% for colloid, tubular, and conventional PDAC, respectively, with the colloid variant demonstrating a more statistically significant favorable outcome than the tubular subtype and PDAC (p = 0.0001) [16].

### Recurrence Patterns

The recurrence rates of resected IPMNs (including non-invasive lesions) have been reported in the literature to be 10–27% [22–25]. The recurrence rate and patterns for IPMNs specifically, however, are poorly described due to most studies being underpowered and lacking long-term follow-up. We most recently reviewed our institution’s data (Annals of Surgery, in press), analyzing 84 patients with IPMNs with a median follow-up of 38 months. We found that IPMNs recurred at a rate of 45% at a median of <2 years, significantly more common (9%), and earlier (>4 years) than non-invasive IPMNs. Of the IPMC lesions that recurred, only 14% of them required a reoperation. It is noteworthy that the recurrence rate of IPMCs was unaffected by adjuvant therapy. Independent predictors of recurrence include tubular invasive type, lymph node involvement, and high-grade dysplasia or cancer at the surgical margin during the index resection. While the recurrence of IPMCs occurred at a median of 19 months after surgery, it could also occur as far out as 11 years, which suggests that these patients will need lifelong postoperative surveillance.
the biological heterogeneity of IPMCs. However, based on our understanding of the natural history of different variants of IPMCs, it is reasonable to recommend adjuvant therapy in patients with tubular IPMCs, IPMCs of gastric epithelial background, or those with regional lymph node involvement.

References

1 Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al: 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surg 2012;152(suppl 1):S4–12.
2 Fernandez-del Castillo C, Targarona J, Thayer SP, et al: Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138:427–433; discussion 433–434.
3 Cauley CE, Waters JA, Dumas RP, et al: Outcomes of primary surveillance for intraductal papillary mucinous neoplasm. J Gastrointest Surg 2012;16:258–267; discussion 266.
4 Kobari M, Egawa S, Shibuya K, et al: Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999;134:1131–1136.
5 Terris B, Ponsot P, Paye F, et al: Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372–1377.
6DOI R, Fujimoto K, Wada M, et al: Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002;132:80–85.
7Matsumoto T, Araki M, Yada K, et al: Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 2003;36:261–265.
8Kitagawa Y, Unger TA, Taylor S, et al: Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg 2003;7:12–18; discussion 18–19.
9 Sugiyama M, Isumaito Y, Abe N, et al: Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003;90:1244–1249.
10 Cripta S, Fernandez-del Castillo C, Salva B, et al: Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 2005;3:213–219.
11 Winter JM, Cameron JL, Campbell KA, et al: 1423 pancreatecodenodensities for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199–1210; discussion 1210–1211.
12 Fernandez-del Castillo C, Morales-Oyarvide V, McGurk D, et al: Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery 2012;152(suppl 1):S56–63.
13 Sohn TA, Yeo CJ, Cameron JL, et al: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788–797; discussion 797–799.
14 D’Angelica M, Brennan MF, Suriawinata AA, et al: Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004;239:400–408.
15 Yamaguchi K, Kamiyama S, Hatori T, et al: Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 2011;40:571–580.
16 Yopp AC, Katabi N, Janakos M, et al: Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg 2011;253:868–874.
17 Minou-Kenudson M, Fernandez-del Castillo C, Baba Y, et al: Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 2011;60:1712–1720.
18 Adsay NV, Merati K, Basturk O, et al: Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an ‘intestinal’ pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004;28:839–848.
19 Yopp AC, Allen PJ: Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg 2010;2:359–362.
20 Partelli S, Fernandez-del Castillo C, Bassi C, et al: Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg 2010;251:477–482.
21 Yamada S, Fujii T, Shimoyama Y, et al: Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol 2014;21:2444–2452.
22 Miller JR, Meyer JE, Waters JA, et al: Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford) 2011;13:759–766.
23 Kang MJ, Jang JY, Lee KB, et al: Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg 2014;260:356–363.
24 Chari ST, Yaday D, Smyrk TC, et al: Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500–1507.
25 Passot G, Lebeau R, Hervieu V, et al: Recurrences after surgical resection of intraductal papillary mucinous neoplasms of the pancreas: a single-center study of recurrence predictive factors. Pancreas 2012;41:137–141.
26 Binkin AV, Binkin SA, Kench JG, et al: Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 2002;50:861–868.
27 Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000;157:755–761.
28 House MG, Guo M, Iacobuzio-Donahue C, et al: Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003;24:193–198.
29 Yeo CJ, Abrams RA, Grochow LB, et al: Pancreatocoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621–633; discussion 633–636.
30 Hsu CC, Herman JM, Corsini MM, et al: Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981–990.
31 Alexander BM, Fernandez-del Castillo C, Ryan DP, et al: Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointestinal Cancer Res 2011;4:116–121.
32 Swartz MJ, Hsu CC, Pawlik TM, et al: Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys 2010;76:839–844.
33 Turrini O, Waters JA, Schnellforter T, et al: Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford) 2010;12:447–55.
34 Mair F, Hammel P, Terris B, et al: Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with conventional ductal adenocarcinoma. Gut 2002;51:717–722.
35 Sadakari Y, Ohuchida K, Nakata K, et al: Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery 2010;147:812–817.

Disclosure Statement

The authors have no conflict of interest to disclose.